Moore RD - Search Results

1

Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Wendel SK, Longosz AF, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Quinn TC, Laeyendecker O. Wendel SK, et al. Among authors: moore rd. AIDS Res Hum Retroviruses. 2017 Apr;33(4):325-327. doi: 10.1089/AID.2016.0105. Epub 2017 Jan 11. AIDS Res Hum Retroviruses. 2017. PMID: 27875908 Free PMC article.

2

Association of medical insurance and other factors with receipt of antiretroviral therapy.

Keruly JC, Conviser R, Moore RD. Keruly JC, et al. Among authors: moore rd. Am J Public Health. 2002 May;92(5):852-7. doi: 10.2105/ajph.92.5.852. Am J Public Health. 2002. PMID: 11988459 Free PMC article.

3

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

4

Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Spacek LA, Griswold M, Quinn TC, Moore RD. Spacek LA, et al. Among authors: moore rd. AIDS. 2003 Jun 13;17(9):1311-7. doi: 10.1097/00002030-200306130-00005. AIDS. 2003. PMID: 12799552

5

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

6

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

7

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

8

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Gallant JE, Parish MA, Keruly JC, Moore RD. Gallant JE, et al. Among authors: moore rd. Clin Infect Dis. 2005 Apr 15;40(8):1194-8. doi: 10.1086/428840. Epub 2005 Mar 17. Clin Infect Dis. 2005. PMID: 15791522 Clinical Trial.

9

An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Moore RD, Keruly JC, Gebo KA, Lucas GM. Moore RD, et al. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):195-8. J Acquir Immune Defic Syndr. 2005. PMID: 15905736

10

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC. Spacek LA, et al. Among authors: moore rd. Clin Infect Dis. 2006 Jan 15;42(2):252-9. doi: 10.1086/499044. Epub 2005 Dec 12. Clin Infect Dis. 2006. PMID: 16355337

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters